SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the activity of fulvestrant in postmenopausal
women with advanced breast cancer failing treatment with non-steroidal or steroidal aromatase
inhibitors by estimating the Clinical Benefit Rate